Genetic Testing Market by Product (Consumables, Equipment, Software & Services), Technology (NGS, PCR, FISH), Testing Type (Predictive & Presymptomatic, Carrier, Prenatal & Newborn, Preimplantation), Methods (Molecular, Genetic, Biochemical), End User (Hospitals, Clinical Labs) - Global Forecast to 2027
“High volume of genetic screening tests to screen cancer, fetal abnormalities, and other genetic anomalies. The increasing trend of next generation screening for various research studies, personalized medicines and direct-to-consumer genetic testing are pushing the growth of the Genetic Testing Market.”
The global Genetic Testing Market is expected to reach USD xx billion by 2027 from USD xx billion in 2022, at a CAGR of xx%. The growth in this market is driven by the increasing prevalence of the genetic disorders, increasing cases of cancer, and genetic anomalies in newborn. The increasing awareness of genetic testing for screening cancer, pre-natal genetic screening of the increasing use of next generation sequencing (NGS) for the studies of various genetic diseases are pushing the growth of the market.
To know about the assumptions considered for the study, Request for Free Sample Report
“The consumables segment held the largest market share in 2021.”
Based on product, the Genetic Testing Market is segmented into consumables, equipment, software and services. The consumable segment held the largest share in 2021, which is driven by the high volume of consumables consumed in the genetic tests.
“The next generation sequencing segment is accounted for the largest share in 2021.”
Based on the technology, the Genetic Testing Market is segmented into Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Chemiluminescence Immunoassay, and Other Technologies. The Next generation Sequencing segment is held the largest share owing to its increasing usage for the detection, studies and management of genetic disorders.
“Asia Pacific is estimated to register the highest CAGR during the study period. North America is expected to dominate the market share”
In this report, the Genetic Testing Market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, Middle East & Africa and Latin America. North America to dominate the market in 2021, owing to its advanced genetic testing technologies, massive volume of genetic testing, and increasing prevalance of genetic disorders. The increasing awarenss and government programs and support for the genetic testing are also promoting the market growth.
Asia Pacific Market is expected to grow at the fastest CAGR during the forecast period of 2022 to 2027, this is attributed to the vast geriatric popualtion, expaniding population base, huge volume of genetic testing due to the massive prevalance of genetic diseases, increasing use of genetic tests for cancer screening, pre-natal screening and other genetic anomalies.
To know about the assumptions considered for the study, download the pdf brochure
Breakdown of primary supply-side interviews, by company type, designation, and region:
- By Company Type - Tier 1: 48%, Tier 2: 40%, and Tier 3: 12%
- By Designation - C-level: 44%, D-level: 30%, and Others: 26%
- By Region: North America (34%), Europe (26%), AsiaPacific (23%), and Rest of the World (17%)
List of Companies Profiled in the Report
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- QIAGEN
- Siemens Healthinier
- Danaher Corporation
- Hologic, Inc.
- PerkinElmer Inc.
- Myriad Genetics Inc.
- Sysmex Corporation
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.4 ECOSYSTEMS ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.6 PRICING ANALYSIS
6 GENETIC TESTING MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 CONSUMABLES
6.3 EQUIPMENT
6.4 SOFTWARE AND SERVICES
6.5 COVID-19 IMPACT ANALYSIS
7 GENETIC TESTING MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 NEXT-GENERATION SEQUENCING
7.3 POLYMERASE CHAIN REACTION
7.4 FLUORESCENCE IN SITU HYBRIDIZATION
7.5 CHEMILUMINESCENCE IMMUNOASSAY
7.6 OTHER TECHNOLOGIES
7.7 COVID-19 IMPACT ANALYSIS
8 GENETIC TESTING MARKET, BY TESTING TYPE
8.1 INTRODUCTION
8.2 PREDICTIVE TESTING AND PRESYMPTOMATIC TESTING
8.3 CARRIER TESTING
8.4 PRENATAL AND NEWBORN TESTING
8.5 PREIMPLANTATION TESTING
8.6 DIAGNOSTIC TESTING
8.7 PHARMACOGENOMIC TESTING
8.8 NUTRIGENOMIC TESTING
8.9 FORENSIC TESTING
8.10 COVID-19 IMPACT ANALYSIS
9 GENETIC TESTING MARKET, BY METHODS
9.1 INTRODUCTION
9.2 MOLECULAR GENETIC TESTING
9.3 CHROMOSOMAL GENETIC TESTING
9.4 BIOCHEMICAL GENETIC TESTING
9.5 OTHERS (IF ANY)
9.6 COVID-19 IMPACT ANALYSIS
10 GENETIC TESTING MARKET, BY END USERS
10.1 INTRODUCTION
10.2 HOSPITALS
10.3 CLINICAL LABORATORIES
10.4 OTHERS (IF ANY)
10.5 COVID-19 IMPACT ANALYSIS
11 GENETIC TESTING MARKET, BY REGION
11.1 INTRODUCTION
11.2 EUROPE
11.2.1 ITALY
11.2.2 GERMANY
11.2.3 FRANCE
11.2.4 UK
11.2.5 SPAIN
11.2.6 REST OF EUROPE
11.3 NORTH AMERICA
11.3.1 US
11.3.2 CANADA
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.6 MIDDLE EAST AND AFRICA
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES
12.1 COMPANY EVALUATION MATRIX DEFINITION & METHODOLOGY
12.2 MARKET SHARE ANALYSIS (2021, % OF USD MILLION)
12.3 COMPETITIVE SCENARIO
12.3.1 PRODUCT LAUNCHES AND APPROVALS
12.3.2 COLLABORATIONS
12.3.3 EXPANSIONS
12.3.4 ACQUISITIONS
12.3.5 OTHER DEVELOPMENTS
12.4 COMPETITIVE LEADERSHIP MAPPING
12.4.1 VENDOR INCLUSION CRITERIA
12.4.2 STARS
12.4.3 EMERGING LEADERS
12.4.4 PERVASIVE
12.4.5 EMERGING COMPANIES
13 COMPANY PROFILES
(Business overview, Products offered, Recent developments)*
13.1 F. HOFFMANN-LA ROCHE LTD.
13.2 ABBOTT LABORATORIES
13.3 THERMO FISHER SCIENTIFIC, INC.
13.4 AGILENT TECHNOLOGIES, INC.
13.5 BIO-RAD LABORATORIES, INC.
13.6 ILLUMINA, INC.
13.7 QIAGEN
13.8 SIEMENS HEALTHINIER
13.9 DANAHER CORPORATION
13.10 HOLOGIC, INC.
13.11 PERKINELMER INC.
13.12 MYRIAD GENETICS INC.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
Growth opportunities and latent adjacency in Genetic Testing Market